Literature DB >> 6350023

Streptokinase and anisoylated streptokinase plasminogen complex. Their action on haemostasis in human volunteers.

D H Staniforth, R A Smith, M Hibbs.   

Abstract

A new fibrinolytic agent, BRL 26921, a member of the novel class of thrombolytic agents; the acyl enzymes, has been compared with streptokinase. It has been shown that this new agent, which can bind to fibrin before releasing activator, does not result in clinically significant destruction of the haemostatic system when compared to an equivalent dose of streptokinase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6350023     DOI: 10.1007/bf00607082

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Molecular mechanism of physiological fibrinolysis.

Authors:  B Wiman; D Collen
Journal:  Nature       Date:  1978-04-06       Impact factor: 49.962

2.  Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.

Authors:  P Friberger; M Knös; S Gustavsson; L Aurell; G Claeson
Journal:  Haemostasis       Date:  1978

3.  Evaluation of a rapid method for the determination of plasma fibrinogen.

Authors:  H B Burmester; K Aulton; G I Horsfield
Journal:  J Clin Pathol       Date:  1970-02       Impact factor: 3.411

4.  Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy.

Authors:  R A Smith; R J Dupe; P D English; J Green
Journal:  Nature       Date:  1981-04-09       Impact factor: 49.962

  4 in total
  4 in total

1.  Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.

Authors:  V J Marder; R L Rothbard; P G Fitzpatrick; C W Francis; E C Norry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.

Authors:  J J Hoffmann; J J Bonnier; J B de Swart; P Custers; M Vijgen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 4.  Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

Authors:  J P Monk; R C Heel
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.